Intravenous immunoglobulin for the treatment of Crohn's disease

Autoimmunity Reviews

Volumn 12, Issue 2, 2012, Pages 275-280

  Rogosnitzky, Moshe ^a   Danks, Rachel ^b   Holt, Daniel ^b  

^a MedInsight Research Institute   (Israel)

^b MedInsight Research Institute   (United Kingdom)

Author keywords

Anti TNF; Crohn's disease; Enterovesical fistula; Inflammatory bowel disease; Intravenous immunoglobulin; Review

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; CORTISONE; DEXCHLORPHENIRAMINE; GAMIMMUNE; IMMUNOGLOBULIN; IMMUNOGLOBULIN 7S; IMMUNOGLOBULIN G; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; PARACETAMOL; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; COLONOSCOPY; CORTICOSTEROID THERAPY; CROHN DISEASE; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEVER; HEADACHE; HUMAN; OUTCOME ASSESSMENT; RELAPSE; REMISSION; REVIEW; SHIVERING; WEIGHT REDUCTION;

CROHN DISEASE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; TREATMENT OUTCOME;

EID: 84870242832     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.04.006     Document Type: Review

References (31)

1. Prefontaine E., Sutherland L.R., MacDonald J.K., Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009, CD000067:1.
2. Ng S.C., Chan F.K., Sung J. Review article: the role of non-biological drugs in refractory inflammatory bowel disease. Aliment Pharmacol Ther 2011, 33:417-427.
3. Tjellstrom B., Stenhammar L., Magnusson K.E., Sandqvist T. Oral immunoglobulin treatment in Crohn's disease. Acta Piediatr 1997, 86:221-223.
4. Cottier H., Haussig A. Immunoglobulin in chronic inflammatory diseases. Vox Sang 1986, 51(Suppl. 2):39-43.
5. Rohr G. Morbus Crohn and colitis ulcerosa: indikationen fur 7S-immunoglobine. Die Gelben Hefte 1988, (Suppl. 1):17-22.
6. Asicura H. Clinical effectiveness and immunological changes in ulcerative colitis by massive. Gastroenterology 1991, 100:A194.
7. Korber J., Kottgen E., Renz H. A case of Crohn's disease with increased CD8 T-cell activation and remission during therapy with intravenous immunoglobulins. Scand J Gastroenterol 1998, 33:1113-1117.
8. Rohr G., Kusterer K., Schille M., Gladisch R., Schwedes U., Teuber J., et al. Treatment of Crohn's disease and ulcerative colitis with 7S-immunoglobulin. Lancet 1987, 17:170.
9. González-Lara V., Carneros J.A., Núñez-Martínez O., Rodríguez C., Escudero M., Álvarez R. The prolonged administration of intravenous immunoglobulins as a treatment for refractory fistulous Crohn's diseases. Gastroenterol Hepatol 2000, 23:12-13.
10. Wolf A., Gaedicke G., Leupold D., Kohne E. Treatment of Crohn disease with intravenous immunoglobulin. Monatsschr Kinderheilkd 1988, 136:101-103.
11. Soreson R.U., Kallick M.D. Clinical uses of intravenous immune globulin. J Clin Apheresis 1988, 4:97-103.
12. Possoz P., Diaz D., Hories P., Michel H. May the administration of high dose intravenous gammaglobulin remove a long term steroid treatment Crohn's disease?. Gastroenterology 1989, 96:A397.
13. Raedler A., Ladehof E., Schug S., Schreiber S., Greten J. Therapy of Crohn's disease with IgM-enriched immunoglobulin. Gastroenterology 1988, 94:A363.
14. Teuber J., Gladisch R., Christophel J., Usadel K.H. Hochdosierte 7S-IgG-Therapie mit Venimmun bei Colitis ulcerosa und Morbus Crohn - klinische Erfahrungen und experimentelle Untersuchungen zum Wirkmechanismus. Infektionen und Autoimmunerkrankungen 1991, 51-61.
15. Schmidt C. Stellenwert der 7S-Immunglobulin-Therapie bei Morbus Crohn und Colitis ulcerosa. Immunmodulatorische Therapie mit Immunglobulinen bei Infektionen und Autoimmunerkrankungen 1995, 132-145. University of Jena Publishing.
16. Raedler A., Ladehoff E., Schug S., Greten H. Adjuvante therapie des Morbus Crohn mit IgM angereichertem Immunoglobulin. Klinisch angewandte Immunologie: Sepsistherapie 1986, 50-58.
17. Rohr G., Uskadel K.H. New aspects for the therapy of Crohn's disease. Klin Wochenschr 1990, 68(Suppl. XXI):64-68.
18. Ochs H.D., Fischer S.H., Christine D.L., Haggitt R.C., Levine D.S. Intravenous immunoglobulin in idiopathic inflammatory bowel disease: results of an open-label therapeutic trial. Immunotherapy with Intravenous Immunoglobulins 1991, 359-376. Academic Press, San Diego. P. Imbach (Ed.).
19. Levine D.S., Fischer S.H., Christie D.L., Haggitt R.C., Ochs H.D. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis. Am J Gastroenterol 1992, 87:91-100.
20. Levine D.S. Immunoglobulin therapy in inflammatory bowel disease. Can J Gastroenterol 1993, 7:187-195.
21. Schmidt C. 7S-Immunoglobulin bei Morbus Crohn. Klinikarzt 1990, 19:552-558.
22. Knoflach G.P., Müller C., Eibl M.M. Crohn disease and intravenous immunoglobulin G. Ann Intern Med 1990, 112:385-386.
23. Chrissafidou A., Malek M., Musch E. Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease. Z Gastroenterol 2007, 45:605-608.
24. Maddur M.S., Kaveri S.V., Bayry J. Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun Rev 2011, 10:809-810.
25. Katz U., Shoenfeld Y., Zandman-Goddard G. Update on intravenous immunoglobulins (IVIg) mechanisms of action and off-label use in autoimmune diseases. Curr Pharm Des 2011, 17:3166-3175. U.
26. Sapir T., Blank M., Shoenfeld Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann N Y Acad Sci 2005, 1051:743-778.
27. Kaveri S.V. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev 2012, 12. Epub ahead of print.
28. Maddur M.S., Hedge P., Sharma M., Kaveri S.V., Bayry J. B cells are resistant to immunomodulation by 'IVIg-educated' dendritic cells. Autoimmun Rev 2011, 11:154-156.
29. Zandman-Goddard G., Krauthammer A., Levy Y., Langevitz P., Shoenfeld Y. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol 2012, 42:247-255.
30. Wong B.J., Cifaldi M.A., Roy S., Skonieczny D.C., Stavrakas S. Analysis of drug and administrating costs allowed by US private and public third-part payers for 3 intravenous biologic agents for rheumatoid arthritis. J Manag Care Pharm 2011, 17:313.
31. Winters J.L., Brown D., Hazard E., Chainani A., Andrezejewski C. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barre syndrome. BMC Health Serv Res 2011, 11:1-8.